Adrian Rawcliffe, Chief Executive Officer at Adaptimmune Therapeutics PLC (ADAP), sold 4,967 shares at $5.33 ($26K) on 2021-01-04, disclosed to the SEC on 2021-01-05.
Open-market sale of $26k ADAP by Chief Executive Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| WVE | SELL | 2025-11-14 | $219K | — | Filing → |
| ADAP | SELL | 2025-01-17 | $18K | — | Filing → |
| ADAP | SELL | 2025-01-15 | $35K | — | Filing → |